Berger Montague Investigates ADMA Biologics Board
Analysis based on 6 articles · First reported Aug 17, 2026 · Last updated Sep 08, 2026
The investigation raises concerns about ADMA Biologics' revenue recognition practices, potentially leading to a decline in investor confidence and stock price. Legal and regulatory scrutiny could result in financial penalties, restatements, or increased litigation costs for the company.
Berger Montague, a national plaintiffs' law firm, announced an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, a biopharmaceutical company. The investigation focuses on whether ADMA engaged in channel-stuffing to drive revenue growth despite declining demand for its flagship product, ASCENIV, an intravenous immune globulin therapy for Primary Humoral Immunodeficiency. The firm is contacting shareholders to gather information and potentially pursue legal action. This investigation was announced via press releases on August 17, August 31, and September 8, 2026, indicating ongoing scrutiny. The allegations, if proven, could have significant implications for ADMA's financial reporting and shareholder trust.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard